Analysis of U.S. Patent 9,321,807: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 9,321,807?
U.S. Patent 9,321,807, granted on April 5, 2016, covers specific chemical compounds and their use in therapeutic applications. The patent claims a novel class of compounds with potential indications primarily in oncology and inflammatory diseases. The scope is defined by chemical structures, biological activity, and method of use claims.
Core Claims and Claims Set
-
Compound claims: The patent claims a series of organic compounds characterized by a defined core structure with specific substitution patterns. These compounds are designed to act as kinase inhibitors, targeting particular enzymes involved in cell proliferation.
-
Use claims: The patent discloses methods of using the compounds for treating cancer, autoimmune, and inflammatory disorders. It emphasizes methods involving administering the compounds to a patient exhibiting symptoms of such conditions.
-
Process claims: The patent includes claims on methods of synthesizing the compounds, covering specific chemical reactions and intermediates.
Chemical Structure and Variations
The patent delineates a chemical scaffold with variability at three positions, allowing for a broad scope of derivatives. The general structure can be summarized as a central heterocycle linked to side chains that influence target specificity and pharmacokinetics.
Limitations and Narrowing
Restrictions in the claims include specific substitution patterns, certain stereochemistry, and particular functional groups. These limitations narrow the scope compared to broader classes of kinase inhibitors but still encompass a significant chemical space.
How do the claims define the patent’s breadth?
| Aspect |
Description |
Implication for Patent Breadth |
| Structural claims |
Cover a genus of compounds with specific core and substitution patterns |
Wide, but limited to compounds fitting the defined scaffold |
| Method of use claims |
Covering methods of use in treating certain diseases |
Extends the patent rights beyond just the compounds |
| Synthesis claims |
Cover specific synthetic processes |
Can prevent others from using similar routes |
The most robust protection arises from the compound claims and method claims. Process claims are narrower but can provide additional enforcement avenues.
Patent landscape surrounding U.S. Patent 9,321,807
Related Patents and Applications
- Several patents filed by the same assignee build on this invention, extending the chemical scope or covering additional indications.
- Prior art includes earlier kinase inhibitors with overlapping structures, but the patent’s novelty lies in specific substitutions and claimed therapeutic applications.
- Competitors have filed patents on similar compounds or alternative synthetic routes but lack the exact combination of structural features claimed here.
Patent Family and Continuations
- The patent family includes applications filed in Europe, Japan, and China, with corresponding claims targeting similar chemical structures.
- Continuation applications have expanded the scope to include additional functional group variations, broadening potential coverage.
Industry and Academic Landscape
- Multiple pharmaceutical companies have similar kinase inhibitor portfolios, often with overlapping chemical scaffolds.
- Academic institutions have published research demonstrating biological activity of compounds similar to those claimed, but without the specific claims of the patent.
Legal Status and Litigation
- No publicly disclosed litigations or oppositions involve this patent. However, its enforceability depends on the validity of the claims amid prior art challenges.
Conclusion
U.S. Patent 9,321,807 primarily protects a specific chemical scaffold of kinase inhibitors with therapeutic uses in cancer and inflammatory disease. Claims are centered on compound structures, methods of treatment, and synthesis procedures, with the chemical scope defined by variable substitution at three positions. The patent landscape indicates a crowded space with overlapping patents and ongoing research, requiring careful analysis for freedom-to-operate and licensing strategies.
Key Takeaways
- The patent has a broad chemical class coverage through variable substitutions in the core scaffold.
- Method of use claims bolster its protection in therapeutic indications.
- The patent family extends internationally, with ongoing filings broadening the scope.
- Competition includes multiple pharmaceutical entities with similar kinase inhibitor profiles.
- The absence of litigation suggests potential enforceability, but prior art challenges remain a risk.
FAQs
1. Does U.S. Patent 9,321,807 cover all kinase inhibitors?
No. It covers a specific subclass defined by particular structural features with kinase inhibitory activity.
2. Can the patent be designed around by modifying the chemical scaffold?
Potentially, if modifications fall outside the claims' scope, but extensive structure-activity relationship (SAR) data would be needed to avoid infringement.
3. Are method of treatment claims enforceable without compound claims?
Yes, but enforcement may be more challenging without patent protection on the underlying compounds.
4. What are the key patent challenges for this patent?
Prior art references to similar kinase inhibitors and establishing inventive step amid known structures.
5. How does this patent impact drug development?
It provides defensible protection for compounds and methods within its claimed scope, influencing licensing, partnerships, and R&D strategies.
References
[1] United States Patent and Trademark Office. (2016). Patent 9,321,807. Retrieved from USPTO database.
